Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer
|
|
- Madlyn Shaw
- 5 years ago
- Views:
Transcription
1 Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer Virginie Westeel, MD, Didier Choma, MD, François Clément, MD, Marie-Christine Woronoff-Lemsi, PhD, Jean-François Pugin, MD, André Dubiez, MD, and Alain Depierre, MD Chest Disease Department and Departments of Thoracic Surgery and Pharmacy, University Hospital, Besançon, France Background. Although a minimal follow-up with periodic clinic visits and chest radiographs is usually recommended after complete operation for non small cell lung cancer, the ideal follow-up has not been defined yet. Objectives of this prospective study were to determine the feasibility of an intensive surveillance program and to analyze its influence on patient survival. Methods. Follow-up consisted of physical examination and chest roentgenogram every 3 months and fiberoptic bronchoscopy and thoracic computed tomographic scan with sections of the liver and adrenal glands every 6 months. Influence of patient and recurrence characteristics on survival from recurrence was successively analyzed using the log-rank test and a Cox model adjusted for treatment. Results. Among the 192 eligible patients, recurrence developed in 136 patients (71%) and was asymptomatic in 36 patients (26%). In 35 patients, recurrence was asymptomatic and detected by a scheduled procedure: thoracic computed tomographic scan in 10 (28%) patients and fiberoptic bronchoscopy in 10. Fifteen patients (43%) had a thoracic recurrence treated with curative intent. From the date of recurrence, 3-year survival was 13% in all patients and 31% in asymptomatic patients whose recurrence was detected by a scheduled procedure. Asymptomatic recurrences (p < 0.001), female sex (p < 0.001), performance status 2 or less (p 0.01), and age 61 years or younger (p 0.01) were shown to be significantly favorable prognostic factors. Conclusions. This intensive follow-up is feasible and may improve survival by detecting recurrences after surgery for non small cell lung cancer at an asymptomatic stage. (Ann Thorac Surg 2000;70: ) 2000 by The Society of Thoracic Surgeons Surgery remains the best chance of cure in non small cell lung cancer, but the risk of recurrence or of new lung cancer is high. The 5-year survival rate observed in patients who have been operated on varies by stage, from 20% to 65%. There is no consensus for the best follow-up of patients after complete resection for non small cell lung cancer. A survey among the members of The Society of Thoracic Surgeons showed a marked variation in surveillance practice in the United States [1, 2]. Moreover, significant differences in follow-up practice patterns can exist within single health-care facilities as shown in the St. Louis Department of Veterans Affairs Medical Center [3]. Wide variations in surveillance testing are also observed in Europe. On the basis of retrospective studies [3 7], it is usually considered that there is no justification for a follow-up surveillance beyond periodic physical examination and chest roentgenogram in operated lung cancer. To clearly evaluate the interest of a more intensive surveillance after lung cancer operation, a randomized trial should be undertaken as it was in breast cancer patients who were operated on [8, 9]. Before initiation of a randomized trial Accepted for publication April 1, Address reprint requests to Dr Westeel, Service de pneumologie, CHU, Hôpital J Minjoz, Blvd Fleming, Besançon, France; virginie.westeel@ufc-chu.univ-fcomte.fr. comparing a strategy including physical examination and chest roentgenogram with a more intensive program, relevant follow-up strategies need to be defined. A prospective study including a cost analysis was performed to evaluate the feasibility and the impact of a standardized follow-up program consisting of physical examination, chest roentgenogram, thoracic computed tomography (CT) scan with sections of the liver and adrenal glands, and fiberoptic bronchoscopy on patient survival. Material and Methods Eligibility Criteria All patients of the Respiratory Medicine Department of Besançon who underwent resection for non small cell lung cancer between January 1980 and December 1993 and whose postoperative care was performed by this department were considered for this study. Patients were eligible if the cancer had been completely resected. Incomplete resections included positive bronchial or pulmonary parenchymal margins and extranodal cancer invasion of mediastinal lymph nodes. Patients who had had a previous malignancy in the 5 years before the operation (except for carcinoma in situ of the uterine cervix and basal cell carcinoma of the skin), patients who died within 30 days of operation, and patients with a 2000 by The Society of Thoracic Surgeons /00/$20.00 Published by Elsevier Science Inc PII S (00)
2 1186 WESTEEL ET AL Ann Thorac Surg INTENSIVE FOLLOW-UP IN RESECTED NSCLC 2000;70: mixed histologic profile that included small cell carcinoma or neuroendocrine tumor cells could not be included. Patients who had undergone primary resection of synchronous brain metastasis were eligible. Informed consent was obtained from all patients, and all procedures were conducted in accord with French ethical guidelines. Preoperative Evaluation Preoperative radiologic evaluation included chest roentgenogram, thoracic CT scan including liver and adrenals, and brain CT scan. Mediastinoscopy was not routinely required but was left to the discretion of investigators. Follow-up Procedures During the first 3 years after the operation, follow-up procedures included: physical examination and chest roentgenogram 1 month after operation and every 3 months thereafter and thoracic CT scan with sections of the liver and adrenal glands and fiberoptic bronchoscopy every 6 months. Between 1980 and 1984, fiberoptic bronchoscopy was planned every 3 months during the first year after operation. Because it was frequently omitted, fiberoptic bronchoscopy was scheduled every 6 months from the first year of surveillance, at the same time as thoracic CT scan, between 1985 and From the fourth to the seventh year after operation, chest roentgenogram was performed every 6 months and thoracic CT scan and fiberoptic bronchoscopy once a year. From the eighth year after operation, surveillance testing only consisted of a yearly chest roentgenogram. Compliance With Follow-up Procedures Compliance with the surveillance procedures was studied in the patients included during the last 4 years of the study. In these patients, the number of chest roentgenograms, thoracic CT scans, and fiberoptic bronchoscopies actually realized until recurrence, death, or June 15, 1997, was calculated and compared with the number of scheduled procedures. The frequency of physical examinations was the same as the frequency of chest roentgenograms, as they were realized at the same visit. Recurrences The criteria reported by Martini and colleagues [10] were used to differentiate second primary lung cancers and lung recurrences. Recurrences were recorded as detected during a scheduled or an unscheduled procedure and as localized within the chest or distant. Unscheduled procedures consisted of additional visits or procedures because of new symptoms. Patients whose tumor recurred were recorded as being either symptomatic or asymptomatic at the time of recurrence. The method by which the recurrence was diagnosed was noted; these included physical examination, chest roentgenogram, CT scan of the chest, CT sections of the liver and adrenal glands, fiberoptic bronchoscopy, and other procedures. Other procedures consisted of procedures different from those included in the program and performed because of new symptoms either detected during a scheduled visit or during an additional visit. Treatment was considered to be curative in intent if the patient had cryotherapy for a carcinoma in situ, underwent complete surgical resection of a chest or brain lesion, or had thoracic radiotherapy or chemoradiation for a local or locoregional recurrence (at most limited to the lung and ipsilateral mediastinum). Palliative therapy was defined as thoracic radiotherapy or chemotherapy for advanced disease. Best supportive care was defined as comfort-oriented care. Survival and Statistical Analysis Potential follow-up was defined as the time elapsed between the date of operation and June 15, Survival was calculated from the date of operation to the date of death or last follow-up visit. In patients whose cancer recurred, survival was also calculated from the date of recurrence to the date of death or last follow-up visit. Disease-free survival was calculated from the date of operation to the date of recurrence or censured at the date of death or last follow-up visit in patients whose disease did not recur. Survival curves were constructed using the Kaplan-Meier method [11]. Survival curves from the date of recurrence were compared by the log-rank test for the following variables: sex, age at operation ( median age versus median age), pathology (adenocarcinoma and large cell carcinoma versus squamous cell carcinoma), performance status ( 2 versus 3 to 4) and symptoms (asymptomatic versus symptomatic) at the time of recurrence, mode of detection of recurrence (scheduled versus unscheduled procedure), diagnostic procedure (physical examination or chest roentgenogram versus fiberoptic bronchoscopy or thoracic CT scan or CT sections of the liver and adrenal glands versus others), site of recurrence (thorax only versus extrathoracic or both intrathoracic and extrathoracic), and disease-free interval ( 1 year versus 1 year). Variables with a p value less than 0.20 were included in a Cox model adjusted for treatment (curative versus palliative versus best supportive care). Qualitative variables of more than two categories were introduced in the model as dummy variables. Second cancers were introduced in the model as time-dependent variables [12]. All statistical analyses were performed using the BMDP software [13]. Cost Analysis The cost was calculated per patient for the median disease-free survival duration. Reimbursement prices are determined for each procedure by the French health-care system. French health-care system 1998 repayment tariffs and 1998 exchange rate ($ French francs) were used. They were $21.43 for a visit, $19.89 for a chest roentgenogram, $ to $ for a thoracic CT scan with sections of the liver and adrenals depending on the age of the scan system, and $ for a fiberoptic bronchoscopy. For one patient, the cost of the follow-up program was the total of the costs for each procedure. For each procedure, the cost was the cost for one procedure multiplied by the number of times this procedure was theoretically performed during the studied period.
3 Ann Thorac Surg WESTEEL ET AL 2000;70: INTENSIVE FOLLOW-UP IN RESECTED NSCLC 1187 Table 1. Characteristics of the 192 Eligible Patients at Operation and Treatments Characteristics n 192 (%) Males/females 177 (92)/15 (8) Pathology Squamous cell a 146 (76) Adenocarcinoma a 43 (22) Large cell carcinoma 4 (2) Pathologic stage I/II 86 (45)/36 (18) IIIa T3/IIIa N2 19 (10)/38 (20) IIIb/IV b 9 (5)/4 (2) Resections Pneumonectomy 113 (59) Lobectomy/bilobectomy c 71 (37)/6 (3) Limited 3 (1) Adjuvant therapy Operation only 124 (65) Operation chemotherapy 33 (17) Operation radiotherapy 29 (15) Operation chemo-radiotherapy 6 (3) a One patient had synchronous squamous cell carcinoma and adenocarcinoma. b Metastatic sites were lung (3 patients) and brain (2 patients). c One patient had a bilobectomy plus a contralateral lobectomy. Compliance With Follow-up Procedures Thirty-eight patients underwent operation between January 1990 and December In these 38 patients, 223 chest roentgenograms were performed for 243 that were scheduled (91.8%), 90 (82.6%) thoracic CT scans with sections of the liver and adrenals and 101 (92.7%) fiberoptic bronchoscopies were performed for a scheduled number of 109 for both. Recurrences One hundred thirty-six patients (71%) had recurrences during the studied period. Median age at the date of recurrence was 61 years (range, 36 to 81 years). Modes of detection, sites and treatments of recurrence, and survival are summarized in Figure 1. Recurrence was detected by a scheduled procedure in 85 patients (63%) and by nonscheduled visits because of new symptoms in 50 patients (37%). In 1 asymptomatic patient, a brain CT scan was systematically performed and detected an asymptomatic brain metastasis. Among the 85 patients whose recurrence was detected by one of the scheduled procedures, 35 (26%) were asymptomatic. Physical examination or chest roentgenogram detected recurrences in 49 patients (36%), thoracic CT scan, in 18 (13%), abdominal CT sections, in 12 (9%), and fiberoptic The cost per years of life potentially gained by thoracic CT scan or fiberoptic bronchoscopy was estimated by dividing the cost because of thoracic CT scan with abdominal sections and fiberoptic bronchoscopy during the median disease-free survival duration for the whole population by the number of years gained. The number of years of life gained by thoracic CT scan or fiberoptic bronchoscopy was the number of asymptomatic patients alive 3 years after recurrence multiplied by 3 among asymptomatic patients who had a thoracic recurrence detected by thoracic CT scan or fiberoptic bronchoscopy and treated with curative intent. Results Patient Characteristics Between January 1980 and December 1993, 298 patients who underwent operations for non small cell lung cancer were monitored by the Chest Disease Department of Besançon. One hundred six patients were not eligible for the following reasons: incomplete resection (76 patients), previous malignancy within the 5 years before operation (16 patients), and death within the 30 days after operation (14 patients). The remaining 192 patients were eligible for the follow-up study. Characteristics of patients at the time of operation and treatments are detailed in Table 1. Median age was 60 years (range, 33 to 81 years). A majority of patients were men and had squamous cell carcinoma. The median potential follow-up was 131 months (range, 46 to 207 months). Fig 1. Recurrences: modes of detection, sites, treatments, and survival. (CI confidence interval; CT computed tomography.)
4 1188 WESTEEL ET AL Ann Thorac Surg INTENSIVE FOLLOW-UP IN RESECTED NSCLC 2000;70: bronchoscopy, in 23 patients (17%). In 9 symptomatic patients (26%) whose recurrence was suspected by a new symptom during a scheduled visit, recurrence was confirmed by other procedures. In symptomatic patients requiring an unscheduled visit for new symptoms, recurrence was confirmed by other procedures in 24 cases (47%). These other diagnostic procedures included brain CT scan (19 patients) and bone scan or radiographs (15 patients). Of the 35 asymptomatic patients whose recurrence was diagnosed by a scheduled procedure, recurrence was diagnosed by thoracic CT scan in 10 patients (29%) and fiberoptic bronchoscopy in 10 patients (29%). Recurrence developed in the chest in 71 patients (52%), outside the chest in 39 patients (29%), and both within and outside the chest in 26 patients (19%). In the 71 patients whose recurrence was diagnosed within the chest only, median time for recurrence was 17 months (range, 1 to 163 months). In the 65 patients whose recurrence occurred outside the chest or both within and outside the chest, median time for recurrence was 9 months (range, 1 to 148 months). Single metastatic sites included brain (18 patients), bone (13 patients), liver (5 patients), and others (3 patients). Recurrence developed in the chest only in 29 (80%) of the 35 asymptomatic patients whose recurrence was detected by a scheduled procedure. Of the 136 recurrences, 35 patients (26%) were treated with curative intent (operation in 22 patients, radiotherapy in 7 patients, chemoradiation in 5 patients, cryotherapy in 1 patient), 71 (52%) received palliative therapy, and 30 (22%) received best supportive care. Treatment was delivered with curative intent for a thoracic recurrence in 15 (43%) of the 36 asymptomatic patients, in 7 (14%) of the 50 symptomatic patients whose recurrence was detected by a scheduled procedure, and in 6 of the 51 patients (12%) whose recurrence was diagnosed by an unscheduled procedure. Recurrence was asymptomatic, treated with curative intent and detected by chest CT scan in 5 of the 136 (4%) patients or by fiberoptic bronchoscopy in 5 (4%) patients. Palliative therapy was given to 17 (47%) of asymptomatic patients, to 35 (70%) of symptomatic patients whose recurrence was detected by one of the follow-up procedures, and to 19 (38%) of symptomatic patients whose recurrence was detected outside the surveillance program. Survival One patient was lost to follow-up 15 days after operation. Median survival was 24 months (range, 1 to 198 months) from the date of operation and 7 months (range, 0 to 164 months) from the date of recurrence. From the date of recurrence, 3-year survival was 13% in the whole population, 31% in asymptomatic patients, 10% in symptomatic patients whose recurrence was detected by one of the follow-up procedures, and 4% in patients whose recurrence was diagnosed by an unscheduled procedure. Among asymptomatic patients, 3-year survival was 40% when the recurrence was exclusively thoracic, 45% when this thoracic recurrence was diagnosed by chest CT scan or fiberoptic bronchoscopy, and 70% when treatment was Table 2. Influence of Patient and Recurrence Characteristics on Survival From Recurrence: Univariate Analysis Variables Median Overall Survival From Recurrence (months) p Value Scheduled/unscheduled 11/ diagnostic procedure Asymptomatic/symptomatic 19/ Thorax only/extrathoracic 12/ or both Disease-free survival from 11/ operation 1/ 1 year Female/male 11/ Adenocarcinoma and large cell/squamous 11/ Diagnostic procedure Physical examination chest x-ray Bronchoscopy CT scan 12 Others 4 Performance status 2/ 2 15/ / 61 years 9/ CT computed tomographic. delivered with curative intent (Fig 1). For the whole population, median disease-free survival was 19 months (range, 1 to 198 months) and the 1-year and 3-year disease-free survival rates were 59% (95% confidence interval, 52% to 66%) and 24% (95% confidence interval, 18% to 30%), respectively. The results of univariate analysis are detailed in Table 2. The detection of recurrence by a scheduled procedure, the absence of symptoms at the time of recurrence, the thoracic site, and a disease-free survival from operation greater than 1 year were found to significantly enhance overall survival from recurrence. No difference in disease-free survival from operation was shown between asymptomatic and symptomatic patients (p 0.25). The results of the Cox model adjusted for treatment are shown in Table 3. Absence of symptoms, female sex, performance status of 2 or less, and age 61 years or younger were found to be significant favorable prognostic factors at the time of recurrence. Occurrence of a second cancer did not enter the model. Second Primary Tumors During this follow-up period, 22 new malignancies developed in the 192 patients (11%): gastrointestinal (5 patients), head and neck (5 patients), lung (3 patients), leukemia (2 patients), esophagus (2 patients), prostate (2 patients), hepatocarcinoma (1 patient), breast (1 patient), and bladder (1 patient). Of 11 (50%) of the 22 second primary cancers located in the surveillance area, 8 (73%) were diagnosed during the 3 postoperative years. Cost Analysis Calculated for a follow-up period of 19 months, which was the median disease-free survival, the cost per patient
5 Ann Thorac Surg WESTEEL ET AL 2000;70: INTENSIVE FOLLOW-UP IN RESECTED NSCLC 1189 Table 3. Cox Model Adjusted for Treatment Variables varied between $1,777 and $1,833, depending on the age of the scan system. For the median of occurrence of a thoracic recurrence of 17 months, the cost per patient varied between $1,231 and $1,291. For the median of occurrence of an extrathoracic or both thoracic and extrathoracic recurrence of 9 months, the cost per patient varied between $679 and $698. Seven patients with an asymptomatic thoracic recurrence detected by CT scan or fiberoptic bronchoscopy and treated with curative intent were alive 3 years after recurrence. The obtained number of years of life gained was 21. The cost because of thoracic CT scan with sections on the liver and adrenal glands and fiberoptic bronchoscopy varied between $270,945 and $281,710. The cost per year of life gained varied between $12,902 and $13,415. Comment Median Overall Survival From Recurrence (months) RR p (95% CI) a Value CU/PA/BSC 26/7/ ( ) 10 4 Asymptomatic/symptomatic 19/ ( ) 10 3 Female/male 11/ ( ) 10 3 Performance status 2/3 4 15/ ( ) 0.01 Age 61/ 61 years 9/ ( ) 0.01 a RR (95% CI) relative risk (95% confidence interval). BSC best supportive care; CU curative; PA palliative. Results of the present study demonstrate that this intensive follow-up is feasible, because 83% to 93% of the scheduled procedures were effectively performed. Even fiberoptic bronchoscopy, considered as the most invasive procedure, was accepted by most patients. Patients who were asymptomatic at the time of recurrence were shown to have a significantly longer survival from recurrence than symptomatic patients. Asymptomatic recurrences were more frequently diagnosed by thoracic CT scan and fiberoptic bronchoscopy than by physical examination and chest roentgenogram. Diversity of follow-up after complete resection of lung cancer shows that the ideal surveillance strategy has not been defined yet [1 3]. The most frequent surveillance includes periodic clinic visits and chest roentgenograms [1 3]. In a retrospective analysis of 182 patients, Virgo and colleagues [3] compared nonintensive with intensive follow-up. Patients were considered to have an intensive follow-up if they had 4 or more clinic visits, blood tests, or chest roentgenograms in any 12-month period, or at least 1 CT scan of the chest, bronchoscopy, or sputum cytology screening. No significant survival advantage was shown for intensive surveillance, but there was a tendency for a longer survival, which suggests that some benefit may exist. In a paper by Walsh and associates [5], the records of 358 lung cancer patients who were operated on and whose follow-up testing procedures and intervals varied were retrospectively reviewed. Patients whose recurrence was asymptomatic were shown to have a significantly longer survival. Survival might benefit from a surveillance strategy that allows the detection of more asymptomatic recurrences than periodic physical examinations and chest roentgenograms would. There is no doubt that only a randomized study can answer the question of whether a more intensive follow-up could enhance survival. We sought to define a follow-up program that would be relevant for a phase III study. The studied surveillance strategy followed principles considered as essential for an effective postoperative testing [7]: The shorter interval between examinations during the first 3 postoperative years, as well as the performance of a surveillance beyond 3 years, was consistent with the time of maximal risk of recurrence and the natural history of the tumor. The tests were directed at the thorax, which was a site of recurrence in 80% of asymptomatic patients. Therapy was available that could result in cure, significant prolongation of life, or palliation of symptoms. Rates of potentially curative and palliative treatments were increased in asymptomatic and symptomatic recurrences detected by one of the follow-up procedures. The initiation of earlier therapy may have improved the outcome compared with therapy given when the patient becomes symptomatic from the tumor. There is an increased risk of second malignancies, especially lung and head and neck cancers, which can be detected by thoracic CT scan or fiberoptic bronchoscopy. Our results are consistent with those of Walsh and coworkers [5]. Indeed, asymptomatic recurrences on which advantages of surveillance testing are focused have been shown to be of better prognosis. As no difference in disease-free interval was shown between asymptomatic and symptomatic patients, lead time bias cannot explain the survival advantage observed in patients who were asymptomatic at the diagnosis of recurrence. The diagnostic procedure (scheduled versus unscheduled) did not enter the multivariate model. However, a majority of recurrences that could be treated with curative intent in asymptomatic patients were diagnosed by chest CT scan or fiberoptic bronchoscopy. A survival advantage might be found with chest CT scan and fiberoptic bronchoscopy in a larger subgroup of patients. A small but significant advantage would be acceptable knowing the number of patients undergoing operation for non small cell lung cancer worldwide. A limitation of this study is the population. Only patients whose postoperative care was performed by our Chest Disease Department were included. They represent only part of the population that has undergone this operation, and this may explain the differences in resection types, sites of recurrences, and survival observed between our series and most published series. In our series, the rates of pneumonectomies of 59% and of
6 1190 WESTEEL ET AL Ann Thorac Surg INTENSIVE FOLLOW-UP IN RESECTED NSCLC 2000;70: thoracic recurrences of 52% were higher than in published studies [3, 5, 6, 10]. Rates of pneumonectomies varied between 17% and 27% in studies including stage I to IIIb tumors [5, 6]. Rates of thoracic recurrences were approximately 20% in most studies [3, 5, 10], with a particularly low rate (7%) in the study reported by Younes and associates [6]. These studies had a surgical recruitment. Patients analyzed in the present study had been referred to the Chest Disease Department rather than directly to the Thoracic Surgery Department, often because their disease presentation was responsible for difficult therapeutic decision. In determining appropriate follow-up practices, besides quantity of life, other important factors to be considered are quality of life and financial aspects. Intensive follow-up might improve quality of life by a better diagnosis and treatment of tobacco- related comorbidities and of postoperative symptoms such as pain or dyspnea. It might also be deleterious on quality of life because of potential anxiety generated by repeated procedures. Younes and colleagues [6] retrospectively evaluated two follow-up strategies. Sixty-seven patients had a follow-up consisting of physical examination every 3 months, chest roentgenogram alternating with thoracic CT scan every 6 months, and liver function tests every year for 2 years. Sixty-three patients were seen on a symptom-oriented basis. The number of health problems other than recurrence requiring emergency room admissions or in-hospital stays was significantly reduced in the strict follow-up group. There is no published study evaluating follow-up strategies after lung cancer resection that includes a quality-of-life questionnaire. The cost for a follow-up period of 19 months was among the lowest when compared with the costs estimated by Virgo and associates [4] from $1,533 to $9,145 for eight published follow-up strategies of increasing intensities for the 5-year period between 1990 and The cost because of thoracic CT scan and fiberoptic bronchoscopy for 1 year of life gained was acceptable. In the study by Younes and coworkers [6], costs of the strict group were significantly higher than those of the symptom group, with no difference in survival after recurrence between the two groups. In the present study, a significant survival advantage was shown in asymptomatic patients whose recurrence was diagnosed during the follow-up strategy, and this seems mostly related to chest CT can and fiberoptic bronchoscopy. This testing strategy is worth being studied within a large randomized study including an indepth cost analysis and evaluation of quality of life and of potential other medical benefits. To detect a 5% survival advantage for the studied follow-up strategy, a total of 2,973 patients who have been operated on should be included. We thank Doctors Claude Prenat, Didier Pernet, Marie-Lise Paquin, Jean Lahourcade, Fabrice Chaussade, and Jean-Louis Cusenier for their cooperation, and Doctor Willard A Fry for having reviewed this paper. References 1. Johnson FE, Naunheim KS, Coplin MA, Virgo KS. Geographic variation in the conduct of patient surveillance after lung cancer surgery. J Clin Oncol 1996;14: Naunheim KS, Virgo KS, Coplin MA, Johnson FE. Clinical surveillance testing after lung cancer operations. Ann Thorac Surg 1995;60: Virgo KS, McKirgan LW, Caputo MCA, et al. Post-treatment management options for patients with lung cancer. Ann Surg 1995;222: Virgo KS, Nauheim KS, McKirgan LW, et al. Cost of patient follow-up after potentially curative lung cancer treatment. J Thorac Cardiovasc Surg 1996;112: Walsh GL, O Connor M, Willis KM, et al. Is follow-up of lung cancer patients after resection medically indicated and cost effective? Ann Thorac Surg 1995;60: Younes RN, Gross JL, Deheinzelin D. Follow-up in lung cancer. How often and for what purpose? Chest 1999;115: Edelman MJ, Meyers FJ, Siegel D. The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. J Gen Intern Med 1997;12: The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer. A multicenter randomized controlled trial. JAMA 1994;271: Rosselli Del Turco MR, Palli D, Carridi A, et al. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. JAMA 1994;271: Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumor in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109: Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53: Cox DR, Oakes D. Time-dependent covariates. In: Cox DR, Oakes D, eds. Analysis of survival data. London: Chapman & Hall Ltd, 1984: Dixon WJ. BMDP statistical software. Berkeley, CA: University of California, 1992.
Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer
ORIGINAL ARTICLE LUNG CANCER Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer Delphine Gourcerol 1,2, Arnaud Scherpereel 1,2, Stephane Debeugny 3, Henri Porte 2,4, Alexis
More informationRelevance of an extensive follow-up after surgery for non-small cell lung cancer
ERJ Express. Published on March 21, 2013 as doi: 10.1183/09031936.00086712 Relevance of an extensive follow-up after surgery for non-small cell lung cancer Delphine Gourcerol¹, ², MD, Arnaud Scherpereel¹,
More informationLung cancer is the leading cause of cancer-related death in many
General Thoracic Surgery Chiu et al Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non small cell lung cancer patients: Preliminary report Chao-Hua Chiu, MD a,d Ming-Sheng
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationPrognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis
< A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationNon-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital
Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Muhammad Rizwan Khan,Sulaiman B. Hasan,Shahid A. Sami ( Department of Surgery, The Aga Khan University Hospital,
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationLONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationSurgical treatment in non-small cell lung cancer with pulmonary oligometastasis
He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,
More informationPulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationProper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer
Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Özcan Birim, MD, A. Pieter Kappetein, MD, PhD, Tom Goorden, MD, Rob J. van Klaveren, MD,
More informationKey words: brain neoplasms; lung neoplasms; neoplasm metastasis; neurosurgery; survival rate; thoracic surgery
Surgical Management of Non-small Cell Lung Cancer With Synchronous Brain Metastases* Pierre Bonnette, MD; Philippe Puyo, MD; Christophe Gabriel, MD; Roger Giudicelli, MD; Jean-François Regnard, MD; Marc
More informationcame from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary
Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationMultifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationSubsequent Pulmonary Resection for Bronchogenic Carcinoma After Pneumonectomy
ORIGINAL ARTICLES: GENERAL THORACIC Subsequent Pulmonary Resection for Bronchogenic Carcinoma After Pneumonectomy Jessica S. Donington, MD, Daniel L. Miller, MD, Charles C. Rowland, BS, Claude Deschamps,
More informationSmall cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
More informationValue of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy
Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A. Hatz, MD, Thomas Helmberger, MD, Udo Loehrs, MD, and Heinrich Fuerst,
More informationDiagnosis and Staging of Non-Small Cell Lung Cancer Carlos Eduardo Oliveira Baleeiro, MD. November 18, 2017
Diagnosis and Staging of Non-Small Cell Lung Cancer Carlos Eduardo Oliveira Baleeiro, MD November 18, 2017 Disclosures I do not have a financial interest/arrangement or affiliation with one or more organizations
More informationAdrenal glands are a common metastatic site for non small cell lung cancer
Surgical treatment of solitary adrenal metastasis from non small cell lung cancer Olaf Mercier, MD, Elie Fadel, MD, PhD, Marc de Perrot, MD, Sacha Mussot, MD, Franco Stella, MD, Alain Chapelier, MD, PhD,
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More informationPulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationPulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience
Pulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience Clinton D. Kemp, MD,* R. Taylor Ripley, MD,* Aarti Mathur, MD, Seth M. Steinberg, PhD, Dao M. Nguyen,
More informationResected Synchronous Primary Malignant Lung Tumors: A Population-Based Study
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationCarcinoma of the Lung in Women
Carcinoma of the Lung in Marvin M. Kirsh, M.D., Jeanne Tashian, M.A., and Herbert Sloan, M.D. ABSTRACT The 5-year survival of 293 men and of 78 women undergoing pulmonary resection and mediastinal lymph
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationTitle: What has changed in the surgical treatment strategies of non-small cell lung cancer in
1 Manuscript type: Original Article DOI: Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in twenty years? A single centre experience Short title: Changes in the
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationPatterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance
Lou et al General Thoracic Surgery Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance Feiran Lou, MD, MS,
More informationTracheal Adenocarcinoma Treated with Adjuvant Radiation: A Case Report and Literature Review
Published online: May 23, 2013 1662 6575/13/0062 0280$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),
More informationInduction chemotherapy followed by surgical resection
Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser
More informationA variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study
ORIGINAL ARTICLE A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study Joon-Hyop Lee, MD, Yoo Seung Chung, MD, PhD,* Young Don Lee, MD, PhD
More informationThe prognostic significance of central fibrosis of adenocarcinoma
Prognostic Significance of the Size of Central Fibrosis in Peripheral Adenocarcinoma of the Lung Kenji Suzuki, MD, Tomoyuki Yokose, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, Kenro Takahashi, MD, Kanji
More informationThe Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma
The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma G. A. Patterson, M.D., R. Ilves, M.D., R. J. Ginsberg, M.D., J. D. Cooper, M.D., T. R. J. Todd, M.D.,
More informationBasaloid Carcinoma of the Lung: A Really Dismal Histologic Variant?
Carcinoma of the Lung: A Really Dismal Histologic Variant? Dae Joon Kim, MD, Kil Dong Kim, MD, Dong Hwan Shin, MD, Jae Y Ro, MD, and Kyung Young Chung, MD Departments of Thoracic and Cardiovascular Surgery,
More informationP sumed to have early lung disease with a favorable
Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,
More informationDEPARTMENT OF ONCOLOGY ELECTIVE
DEPARTMENT OF ONCOLOGY ELECTIVE 2015-2016 www.uwo.ca/oncology Oncology Elective Program Administrator: Ms. Kimberly Trudgeon Room A4-901C (Admin) LHSC London Regional Cancer Centre (Victoria Campus) Phone:
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationSite of Recurrence in Patients. of the Lung Resected for Cure. with Stages I and I1 Carcinoma
Site of Recurrence in Patients with Stages I and I1 Carcinoma of the Lung Resected for Cure Steven C. Immerman, M.D., Robert M. Vanecko, M.D., Willard A. Fry, M.D., Louis R. Head, M.D., and Thomas W. Shields,
More informationSpecial Treatment Issues in Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Special Treatment Issues in Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationLung cancer is the leading cause of cancer death in the United States
Surveillance computed tomography after complete resection for non small cell lung cancer: Results and costs Robert J. Korst, MD a,b Heather T. Gold, PhD c Michael S. Kent, MD d Jeffrey L. Port, MD a Paul
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationLong-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer
ORIGINAL ARTICLE Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer Ryo Maeda, MD,* Junji Yoshida, MD,* Genichiro Ishii, MD, Keiju Aokage, MD,*
More informationImpact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer
Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Jakob R. Izbicki, MD, Bernward Passlick, MD, Ortrud Karg, MD, Christian Bloechle, MD, Klaus Pantel, MD, Wolfram
More informationSmall-cell lung cancer (SCLC) represents approximately
Original Article Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn G. Hancock, BS, Daniel J. Boffa, MD,
More informationKBP2000-articles. [Five year survival for lung cancer patients managed in general hospitals]
1. Rev Mal Respir. 2009 Jan;26(1):37-44. KBP2000-articles [Five year survival for lung cancer patients managed in general hospitals] Grivaux M, Zureik M, Marsal L, Asselain B, Peureux M, Chavaillon JM,
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationLung cancer is one of the most common and most. Delays in the Diagnosis and Treatment of Lung Cancer*
Delays in the Diagnosis and Treatment of Lung Cancer* Eija-Riitta Salomaa, MD, PhD; Susanna Sällinen, BM; Heikki Hiekkanen, MSc; and Kari Liippo, MD, PhD Study objectives: This study was undertaken to
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationsarcoma Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ.
1994, The British Journal of Radiology, 67, 129-135 Lung metastasectomy sarcoma in patients with soft tissue 1 M H ROBINSON, MD, MRCP, FRCR, 2 M SHEPPARD, FRCPATH, 3 E MOSKOVIC, MRCP, FRCR and 4 C FISHER,
More informationThe Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
More informationRetroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients
Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients INGO ALLDINGER 1,2, QIN YANG 3, CHRISTIAN PILARSKY 1, HANS-DETLEV SAEGER 1, WOLFRAM T. KNOEFEL
More informationPAPER. See Invited Critique at end of article
PAPER Systematic Postoperative Radiologic Follow-up in Patients With Non Small Cell Lung Cancer for Detecting Second Primary Lung Cancer in Stage IA Jeffrey P. Lamont, MD; James T. Kakuda, MD; David Smith,
More information24 Ann Thorac Surg 46:24-28, July Copyright by The Society of Thoracic Surgeons
Surgical Management of Lung Cancer with Solitary Cerebral Metastasis John R. Hankins, M.D., John E. Miller, M.D., Michael Salcman, M.D., Frank Ferraro, M.D., David C. Green, M.D., Safuh Attar, M.D., and
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationM expected to arise in 1.6% to 3.0% of all patients. Multiple Primary Lung Carcinomas: Prognosis and Treatment
Multiple Primary Lung Carcinomas: Prognosis and Treatment Todd K. Rosengart, MD, Nael Martini, MD, Pierre Ghosn, MD, and Michael Burt, MD, PhD Thoracic Service, Department of Surgery, Memorial-Sloan Kettering
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationDespite advances in radiation therapy, chemotherapy, Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer
Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer Matthew D. Taylor, MD, Alykhan S. Nagji, MD, Castigliano M. Bhamidipati, DO, MS, Nicholas Theodosakis, BS, Benjamin D. Kozower,
More informationEvaluation of prognostic scoring systems for bone metastases using single center data
MOLECULAR AND CLINICAL ONCOLOGY 3: 1361-1370, 2015 Evaluation of prognostic scoring systems for bone metastases using single center data HIROFUMI SHIMADA 1, TAKAO SETOGUCHI 2, SHUNSUKE NAKAMURA 1, MASAHIRO
More information